Dermatologic manifestations of Crohn disease in children: response to infliximab.
Identifieur interne : 003E04 ( PubMed/Checkpoint ); précédent : 003E03; suivant : 003E05Dermatologic manifestations of Crohn disease in children: response to infliximab.
Auteurs : Subra Kugathasan [États-Unis] ; Adrian Miranda ; James Nocton ; Beth A. Drolet ; Carolyn Raasch ; David G. BinionSource :
- Journal of pediatric gastroenterology and nutrition [ 0277-2116 ] ; 2003.
Descripteurs français
- KwdFr :
- Adolescent, Anticorps monoclonaux (effets indésirables), Anticorps monoclonaux (usage thérapeutique), Enfant, Humains, Infliximab, Lymphoedème (traitement médicamenteux), Lymphoedème (étiologie), Maladie de Crohn (), Mâle, Produits dermatologiques (effets indésirables), Produits dermatologiques (usage thérapeutique), Pyodermie phadégénique (traitement médicamenteux), Pyodermie phadégénique (étiologie), Résultat thérapeutique, Érythème noueux (traitement médicamenteux), Érythème noueux (étiologie).
- MESH :
- effets indésirables : Anticorps monoclonaux, Produits dermatologiques.
- traitement médicamenteux : Lymphoedème, Pyodermie phadégénique, Érythème noueux.
- usage thérapeutique : Anticorps monoclonaux, Produits dermatologiques.
- étiologie : Lymphoedème, Pyodermie phadégénique, Érythème noueux.
- Adolescent, Enfant, Humains, Infliximab, Maladie de Crohn, Mâle, Résultat thérapeutique.
English descriptors
- KwdEn :
- Adolescent, Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal (therapeutic use), Child, Crohn Disease (complications), Dermatologic Agents (adverse effects), Dermatologic Agents (therapeutic use), Erythema Nodosum (drug therapy), Erythema Nodosum (etiology), Humans, Infliximab, Lymphedema (drug therapy), Lymphedema (etiology), Male, Pyoderma Gangrenosum (drug therapy), Pyoderma Gangrenosum (etiology), Treatment Outcome.
- MESH :
- chemical , adverse effects : Antibodies, Monoclonal, Dermatologic Agents.
- chemical , therapeutic use : Antibodies, Monoclonal, Dermatologic Agents.
- complications : Crohn Disease.
- drug therapy : Erythema Nodosum, Lymphedema, Pyoderma Gangrenosum.
- etiology : Erythema Nodosum, Lymphedema, Pyoderma Gangrenosum.
- Adolescent, Child, Humans, Infliximab, Male, Treatment Outcome.
Abstract
Dermatologic extraintestinal manifestations of Crohn disease may be refractory to treatment with corticosteroids and immunomodulators. The authors describe four children with Crohn disease with dermatologic manifestations: pyoderma gangrenosum, orofacial involvement, erythema nodosum, and idiopathic lymphedema. These dermatologic conditions were unresponsive to conventional therapy but had rapid and sustained response to the anti-TNF-alpha antibody infliximab. No adverse reactions occurred. Infliximab should be considered for treating the extraintestinal dermatologic manifestations of Crohn disease in children.
PubMed: 12883301
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:12883301Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dermatologic manifestations of Crohn disease in children: response to infliximab.</title><author><name sortKey="Kugathasan, Subra" sort="Kugathasan, Subra" uniqKey="Kugathasan S" first="Subra" last="Kugathasan">Subra Kugathasan</name><affiliation wicri:level="1"><nlm:affiliation>Division of Pediatric Gastroenterology and Nutrition, Children's Hospital of Wisconsin, Milwaukee, Wisconsin 53226, USA. skuga@mcw.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pediatric Gastroenterology and Nutrition, Children's Hospital of Wisconsin, Milwaukee, Wisconsin 53226</wicri:regionArea><wicri:noRegion>Wisconsin 53226</wicri:noRegion></affiliation></author><author><name sortKey="Miranda, Adrian" sort="Miranda, Adrian" uniqKey="Miranda A" first="Adrian" last="Miranda">Adrian Miranda</name></author><author><name sortKey="Nocton, James" sort="Nocton, James" uniqKey="Nocton J" first="James" last="Nocton">James Nocton</name></author><author><name sortKey="Drolet, Beth A" sort="Drolet, Beth A" uniqKey="Drolet B" first="Beth A" last="Drolet">Beth A. Drolet</name></author><author><name sortKey="Raasch, Carolyn" sort="Raasch, Carolyn" uniqKey="Raasch C" first="Carolyn" last="Raasch">Carolyn Raasch</name></author><author><name sortKey="Binion, David G" sort="Binion, David G" uniqKey="Binion D" first="David G" last="Binion">David G. Binion</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12883301</idno><idno type="pmid">12883301</idno><idno type="wicri:Area/PubMed/Corpus">004214</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004214</idno><idno type="wicri:Area/PubMed/Curation">004214</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004214</idno><idno type="wicri:Area/PubMed/Checkpoint">004214</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004214</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dermatologic manifestations of Crohn disease in children: response to infliximab.</title><author><name sortKey="Kugathasan, Subra" sort="Kugathasan, Subra" uniqKey="Kugathasan S" first="Subra" last="Kugathasan">Subra Kugathasan</name><affiliation wicri:level="1"><nlm:affiliation>Division of Pediatric Gastroenterology and Nutrition, Children's Hospital of Wisconsin, Milwaukee, Wisconsin 53226, USA. skuga@mcw.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pediatric Gastroenterology and Nutrition, Children's Hospital of Wisconsin, Milwaukee, Wisconsin 53226</wicri:regionArea><wicri:noRegion>Wisconsin 53226</wicri:noRegion></affiliation></author><author><name sortKey="Miranda, Adrian" sort="Miranda, Adrian" uniqKey="Miranda A" first="Adrian" last="Miranda">Adrian Miranda</name></author><author><name sortKey="Nocton, James" sort="Nocton, James" uniqKey="Nocton J" first="James" last="Nocton">James Nocton</name></author><author><name sortKey="Drolet, Beth A" sort="Drolet, Beth A" uniqKey="Drolet B" first="Beth A" last="Drolet">Beth A. Drolet</name></author><author><name sortKey="Raasch, Carolyn" sort="Raasch, Carolyn" uniqKey="Raasch C" first="Carolyn" last="Raasch">Carolyn Raasch</name></author><author><name sortKey="Binion, David G" sort="Binion, David G" uniqKey="Binion D" first="David G" last="Binion">David G. Binion</name></author></analytic><series><title level="j">Journal of pediatric gastroenterology and nutrition</title><idno type="ISSN">0277-2116</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Child</term><term>Crohn Disease (complications)</term><term>Dermatologic Agents (adverse effects)</term><term>Dermatologic Agents (therapeutic use)</term><term>Erythema Nodosum (drug therapy)</term><term>Erythema Nodosum (etiology)</term><term>Humans</term><term>Infliximab</term><term>Lymphedema (drug therapy)</term><term>Lymphedema (etiology)</term><term>Male</term><term>Pyoderma Gangrenosum (drug therapy)</term><term>Pyoderma Gangrenosum (etiology)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Anticorps monoclonaux (effets indésirables)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Enfant</term><term>Humains</term><term>Infliximab</term><term>Lymphoedème (traitement médicamenteux)</term><term>Lymphoedème (étiologie)</term><term>Maladie de Crohn ()</term><term>Mâle</term><term>Produits dermatologiques (effets indésirables)</term><term>Produits dermatologiques (usage thérapeutique)</term><term>Pyodermie phadégénique (traitement médicamenteux)</term><term>Pyodermie phadégénique (étiologie)</term><term>Résultat thérapeutique</term><term>Érythème noueux (traitement médicamenteux)</term><term>Érythème noueux (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Dermatologic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Dermatologic Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Crohn Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Erythema Nodosum</term><term>Lymphedema</term><term>Pyoderma Gangrenosum</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Produits dermatologiques</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Erythema Nodosum</term><term>Lymphedema</term><term>Pyoderma Gangrenosum</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphoedème</term><term>Pyodermie phadégénique</term><term>Érythème noueux</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Produits dermatologiques</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term><term>Pyodermie phadégénique</term><term>Érythème noueux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Humans</term><term>Infliximab</term><term>Male</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Enfant</term><term>Humains</term><term>Infliximab</term><term>Maladie de Crohn</term><term>Mâle</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dermatologic extraintestinal manifestations of Crohn disease may be refractory to treatment with corticosteroids and immunomodulators. The authors describe four children with Crohn disease with dermatologic manifestations: pyoderma gangrenosum, orofacial involvement, erythema nodosum, and idiopathic lymphedema. These dermatologic conditions were unresponsive to conventional therapy but had rapid and sustained response to the anti-TNF-alpha antibody infliximab. No adverse reactions occurred. Infliximab should be considered for treating the extraintestinal dermatologic manifestations of Crohn disease in children.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12883301</PMID><DateCreated><Year>2003</Year><Month>07</Month><Day>28</Day></DateCreated><DateCompleted><Year>2004</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0277-2116</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of pediatric gastroenterology and nutrition</Title><ISOAbbreviation>J. Pediatr. Gastroenterol. Nutr.</ISOAbbreviation></Journal><ArticleTitle>Dermatologic manifestations of Crohn disease in children: response to infliximab.</ArticleTitle><Pagination><MedlinePgn>150-4</MedlinePgn></Pagination><Abstract><AbstractText>Dermatologic extraintestinal manifestations of Crohn disease may be refractory to treatment with corticosteroids and immunomodulators. The authors describe four children with Crohn disease with dermatologic manifestations: pyoderma gangrenosum, orofacial involvement, erythema nodosum, and idiopathic lymphedema. These dermatologic conditions were unresponsive to conventional therapy but had rapid and sustained response to the anti-TNF-alpha antibody infliximab. No adverse reactions occurred. Infliximab should be considered for treating the extraintestinal dermatologic manifestations of Crohn disease in children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kugathasan</LastName><ForeName>Subra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology and Nutrition, Children's Hospital of Wisconsin, Milwaukee, Wisconsin 53226, USA. skuga@mcw.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nocton</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Drolet</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Raasch</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Binion</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pediatr Gastroenterol Nutr</MedlineTA><NlmUniqueID>8211545</NlmUniqueID><ISSNLinking>0277-2116</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003879">Dermatologic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003879" MajorTopicYN="N">Dermatologic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004893" MajorTopicYN="N">Erythema Nodosum</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017511" MajorTopicYN="N">Pyoderma Gangrenosum</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12883301</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Binion, David G" sort="Binion, David G" uniqKey="Binion D" first="David G" last="Binion">David G. Binion</name><name sortKey="Drolet, Beth A" sort="Drolet, Beth A" uniqKey="Drolet B" first="Beth A" last="Drolet">Beth A. Drolet</name><name sortKey="Miranda, Adrian" sort="Miranda, Adrian" uniqKey="Miranda A" first="Adrian" last="Miranda">Adrian Miranda</name><name sortKey="Nocton, James" sort="Nocton, James" uniqKey="Nocton J" first="James" last="Nocton">James Nocton</name><name sortKey="Raasch, Carolyn" sort="Raasch, Carolyn" uniqKey="Raasch C" first="Carolyn" last="Raasch">Carolyn Raasch</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Kugathasan, Subra" sort="Kugathasan, Subra" uniqKey="Kugathasan S" first="Subra" last="Kugathasan">Subra Kugathasan</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003E04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:12883301
|texte= Dermatologic manifestations of Crohn disease in children: response to infliximab.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:12883301" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |